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miRNAs as potential biomarkers 
in early breast cancer detection 
following mammography
Sidney W. Fu1*, Woojin Lee1, Caitrin Coffey1, Alexa Lean1, Xiaoling Wu1,2, Xiaohui Tan1, Yan‑gao Man3 
and Rachel F. Brem4
Abstract 
Breast cancer is the most common cancer among American women, except for skin cancers. About 12 % women in 
the United States will develop invasive breast cancer during their lifetime. Currently one of the most accepted model/
theories is that ductal breast cancer (most common type of breast cancer) follows a linear progression: from normal 
breast epithelial cells to ductal hyperplasia to atypical ductal hyperplasia (ADH) to ductal carcinoma in situ (DCIS), 
and finally to invasive ductal carcinoma (IDC). Distinguishing pure ADH diagnosis from DCIS and/or IDC on mam‑
mography, and even combined with follow‑up core needle biopsy (CNB) is still a challenge. Therefore subsequent 
surgical excision cannot be avoided to make a definitive diagnosis. MicroRNAs (miRNAs) are a highly abundant class of 
endogenous non‑coding RNAs, which contribute to cancer initiation and progression, and are differentially expressed 
between normal and cancer tissues. They can function as either tumor suppressors or oncogenes. With accumulating 
evidence of the role of miRNAs in breast cancer progression, including our own studies, we sought to summarize the 
nature of early breast lesions and the potential use of miRNA molecules as biomarkers in early breast cancer detec‑
tion. In particular, miRNA biomarkers may potentially serve as a companion tool following mammography screening 
and CNB. In the long‑term, a better understanding of the molecular mechanisms underlying the miRNA signatures 
associated with breast cancer development could potentially result in the development of novel strategies for disease 
prevention and therapy.
© 2016 Fu et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://
creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided 
you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate 
if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/
zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Breast cancer is one of the most commonly occurring 
cancers among American women and is the second lead-
ing cause of cancer-related deaths. Approximately 1 in 
8 American women (12  %) will develop invasive breast 
cancer in their lifetime, and it is estimated that there 
will be 231,840 new cases of invasive cancer, 60,290 new 
cases of noninvasive, in  situ cancer, and 40,290 deaths 
resulting from breast cancer in 2015 [1]. With the cur-
rent focus on early detection and increased utilization of 
mammography, more and more non-malignant lesions, 
such as atypical ductal hyperplasia (ADH), ductal carci-
noma in situ (DCIS), atypical lobular hyperplasia (ALH), 
and lobular carcinoma in situ (LCIS), are detected. These 
lesions are considered one of the most significant risk 
factors for developing invasive carcinoma [1].
Although the death rates from breast cancer continue 
to decline as a result of the increased utilization of mam-
mography, it is not a definitive early screening tool due 
to its limited sensitivity and specificity [2]. Fayanju et al. 
reported that about 40 % of the 9000 registrants surveyed 
refused to use mammography due to “fears of cost,” while 
another 13  % refused to use it due to “mammogram-
related pain [3].”
Over the past decade, research has largely shifted focus 
from mRNA biomarkers to microRNAs (miRNAs) as 
a new potential screening biomarker for breast cancer. 
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In numerous studies, including our own, researchers 
have found miRNAs to be aberrantly expressed in tis-
sue and serum/plasma in patients with breast cancer 
[4–6]. Although the role of miRNAs in carcinogenesis is 
unclear, evidence suggests that miRNAs are involved in 
the initial development and progression of breast cancer 
by modulating the expression of their target proto-onco-
genes or tumor suppressor genes (TSG) at the posttran-
scriptional level [4]. We, as well as others (FFPE and 638 
paper), have identified numerous miRNAs that are aber-
rantly expressed during breast cancer progression, indi-
cating that miRNAs may serve as a new noninvasive, 
cost-effective screening tool, as well as a companion tool 
to be used in conjunction with mammography for more 
accurate and specific diagnoses [5, 6]. Furthermore, there 
are now ongoing studies on differential miRNA expres-
sion among different pathological stages of breast leisons: 
ADH, DCIS and IDC [6].
To distinguish pure ADH diagnosis from advanced 
lesions, such as DCIS and/or IDC following a mammog-
raphy, and even combined with follow-up core needle 
biopsy CNB is still a challenge. In this review, we summa-
rized the nature of early breast lesions and the potential 
use of miRNA molecules as biomarkers in early breast 
cancer detection. In particular, miRNA biomarkers may 
potentially serve as a companion tool following mam-
mography screening and CNB. In the long-term, a better 
understanding of the molecular mechanisms underly-
ing the miRNA signatures associated with breast cancer 
development could potentially result in the development 
of novel strategies for disease prevention and therapy.
Linear model of breast cancer progression
The relationship between ADH, DCIS, and invasive can-
cer is not fully understood. Historically, breast cancer 
was viewed as a progression from normal epithelial cells 
to hyperplasia (with or without atypia), to in  situ carci-
noma, eventually resulting in invasive carcinoma and 
metastasis. The most widely accepted model of breast 
cancer development at the present time is that ductal 
cells undergo a neoplastic transformation which starts 
from normal epithelium to flat epithelial atypia (FEA), 
evolving to atypical ductal hyperplasia (ADH), into ductal 
carcinoma in situ (DCIS), and finally, into invasive ductal 
carcinoma (IDC). This model is supported by genomic 
and immunohistochemical data which shows distinct 
features at each stage in development [7]. The current 
understanding of breast cancer development supports 
this model, placing invasive cancer at the end of a multi-
stage transition from normal breast epithelium; however, 
recent discoveries in molecular genetics and immunohis-
tochemistry have highlighted the complexity of the pro-
cess, identifying many different and divergent pathways 
resulting in invasive cancer. Cancer cells undergo their 
characteristic changes over a significant timeframe, as 
genes are activated and inactivated in a series of steps [8]. 
Over the course of tumorigenesis, these various cellular 
and genetic changes present as pathologically distinct 
entities.
Via a model of continuation, including FEA, ADH, 
DCIS, and IDC, is supported by morphological, epide-
miological, and immunohistochemical data, as well as 
genomic and transcriptomic studies. Patterns of genomic 
changes in DCIS, which parallel those occurring in IDC, 
have been previously discussed. FEA and ADH also dem-
onstrate similar distinct genetic changes, which overlap 
with some of those of low-grade DCIS [7]. Notably, the 
current evidence supports ADH as the precursor for 
low-grade, but not high-grade, DCIS; the latter which 
is believed to have a distinct progression, which may 
include adenosis. Furthermore, there is evidence for pro-
gressive allelic damage from stages of ADH to DCIS and 
finally IDC [8].
The current clinical approach used to prevent breast 
cancer involves an attempt to diagnose at the earliest 
possible time, which is the most easily treatable stage in 
order to maximize the chances for positive outcomes. 
Thus, improving our understanding of early stage can-
cers, as well as pre-neoplastic processes in the breast, 
is crucial to improving future therapy. ADH represents 
a crucial pathological stage in the transition from what 
is considered normal to what is considered cancerous 
in ductal cells. Ductal subtype accounts for 40–75  % of 
diagnosed breast cancer cases [7]. We are currently aware 
of many of the molecular biomarkers that may be indica-
tive of a development from normal breast epithelium to 
ADH, which will be discussed in detail below. Despite 
our current capabilities, it is important to recognize that 
ADH is not an obligate precursor to in  situ or invasive 
cancer, as noted by Kuerer, as only 14–50  % of women 
with ADH or DCIS will develop invasive cancer in their 
lifetime if left untreated [9]. Additionally, there have been 
studies that show the changes of molecular markers that 
occur during the DCIS stage actually contribute to the 
invasive characteristics of cancer. Therefore, continued 
efforts to understand the linear view of breast cancer 
progression and, in particular, what causes this develop-
ment from normal, to premalignant, to malignant stages 
will offer necessary information in efforts to develop new 
effective treatments.
Distinction between ADH and DCIS
It is important to recognize the differences between ADH 
and DCIS, as they are both noninvasive lesions with sev-
eral overlapping characteristics. ADH is a benign breast 
condition characterized pathologically by some, but not 
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all. ADH is seen in 1–9  % of core needle biopsies [10], 
but is clinically noteworthy as a marker for risk of future 
breast cancer development, and for its frequent asso-
ciation with DCIS and invasive carcinoma upon surgical 
excision. ADH is now considered a non-obligate precur-
sor for low-grade DCIS; in fact, the distinction between 
ADH and DCIS is often unclear, causing diagnosis to 
vary among institutions.
Although the distinction between ADH and DCIS is 
unclear, DCIS is often categorized as non-invasive breast 
cancer. Histologically, DCIS shows disorganized ductal 
cells as opposed to ADH, which exhibits normal duct 
cells with plugged lumens. The ADH is usually defined 
as a mass less than 2 mm in size, while DCIS is greater 
than 2  mm. Additionally, low-grade DCIS is defined as 
a mass that includes two or more breast ducts [7]. Thus, 
DCIS is often categorized as the following stage of ADH. 
If DCIS is not surgically removed, it carries a higher risk 
of becoming invasive cancer than ADH. DCIS also has a 
higher rate of recurrence, at 30 % within the 5–10 years 
after initial diagnosis [8].
Pathological findings
Mammographic screening, which has resulted in a 
reduction in mortality rates due to breast cancer, has also 
led to increased diagnosis of benign, non-palpable breast 
lesions, including atypical, high-risk lesions [11]. ADH, 
for instance, is diagnosed in the breast most often via 
core needle biopsy or surgical excision. Historically, ADH 
was a diagnosis of exclusion; the diagnosis was reserved 
for lesions whose cells resembled low-grade DCIS but did 
not fulfill all criteria for DCIS [12]. Though the criteria 
for a diagnosis of ADH have been refined, histopathologi-
cal distinctions between ADH and some low-grade DCIS 
remains problematic. Diagnosis is primarily quantitative, 
as cellular appearance is similar. Distinction between 
ADH and DCIS is based on size and involvement, as 
mentioned above.
Current diagnosis of ADH involves examination of 
three variables: architectural pattern, cytology, and dis-
ease extent [13]. The cells of ADH are small to medium 
sized, round, cuboidal, or polygonal shaped, regularly 
arranged, and hyper-chromatic with evenly distrib-
uted nuclei and only small, singular nucleoli. Small foci 
of necrosis are uncommon, yet may be present and do 
not necessarily indicate DCIS [13]. Monotonous cells, 
uniformly spaced with rigid secondary spaces, and low-
grade nuclei, characterize cells of both ADH and DCIS. 
Regardless of lesion size, partial involvement of spaces 
supports a diagnosis of ADH. The diagnosis of DCIS is 
generally only made when a lesion meets these criteria: 
either a diameter greater than 2  mm or more than two 
separate duct spaces, as these have been associated with 
increased risk for breast cancer [14].
It has been noted that ADH is thought to lie on a histo-
pathological spectrum between usual hyperplasia (lack-
ing atypia) and low-grade DCIS. Usual hyperplasia differs 
in appearance from ADH in variability of cells, indistinct 
cell borders, and nuclear overlap, with irregular second-
ary spaces [15].
Due to the similarities in cellular appearance, particu-
larly between ADH and low-grade DCIS, as well as the 
small size of cores resulting from minimally invasive 
breast biopsy, pathological diagnosis remains compli-
cated. In fact, accurate diagnosis of ADH requires mor-
phological, histological, and architectural size criteria 
of a lesion, which may be interrupted by core biopsy 
placement [13]. For this reason diagnosis is not always 
reproducible between pathologists, and many argue that 
accurate diagnosis of ADH can only be made from exci-
sional biopsy. In a study involving six experienced pathol-
ogists who reviewed cases of usual ductal hyperplasia 
(UDH), ADH, and DCIS, all six were able to reach con-
sensus on only 58 % of the cases [15]. There has, to date, 
been no biomarker identified that is more useful than 
histopathologic diagnosis, though epigenetic changes 
associated with ADH and DCIS have been the subject 
of much recent research (see below “Biological findings” 
section) and may aid in the development of a reliable 
diagnosis in the future.
Clinical implications
The advent of population-based mammography screen-
ing has led to the increased detection of invasive breast 
cancers as well as a larger number of non-invasive cancer 
precursors, such as DCIS, and non-cancerous, high-risk 
lesions such as ADH. Though some consider ADH to be 
associated with over diagnosis, clinical diagnosis of ADH 
has two important implications:
(1) In approximately 20–50 % of ADH cases an imme-
diately adjacent cancer is found upon surgical excision, 
and as a result excision is recommended for all cases 
[16]. (2) Diagnosis of ADH is associated with a 4–5 
times increased risk of development of breast cancer at 
a median follow up of 17 years, a risk which is increased 
to 8–10 times as likely in women whose family history 
includes a primary relative with breast cancer [17].
Risk assessment is important as it includes a need for 
vigilant annual mammographic screenings and requires 
annual breast MRIs; these preventative measures may 
include the consideration of utilizing chemopreventa-
tive agents such as Tamoxifen, which have been shown to 
reduce the risk of developing breast cancer. Additionally, 
the National Surgical Adjuvant Breast and Bowel Project 
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found that Tamoxifen can reduce risk of breast cancer by 
approximately 50 % in high-risk women, and has showed 
an astounding 86 % decrease in incidents of breast can-
cer among women with a history of ADH. These findings 
support the importance of reliable ADH diagnosis pro-
cedures, as the utilization of chemoprophylaxis selective 
estrogen reuptake modulators (SERMs) to treat breast 
cancer may be an effective tool in reducing mortality 
[18].
In the case of a suspicious lesion sampled by CNB 
which results in a diagnosis of ADH, standard follow-
up care is currently the surgical excision of the lesion for 
all patients, due to risk of associated cancer foci. Adja-
cent breast cancer is found in 18–48  % of cases with a 
14-gauge needle and 19–25  % with an 11-gauge needle, 
with some estimates even higher [10]. Unfortunately, this 
practice subjects patients to the risks associated with sur-
gery, discomfort, and what may be unnecessary cost, as 
the majority patients with ADH do not have an associ-
ated carcinoma and many will not develop breast cancer 
in their lifetime.
Current difficulties in the clinical management of ADH 
are the inability to reliably assess risk, or the presence of 
an adjacent cancer, and to identify prospective patients 
who may not require surgical excision. Many studies 
have been conducted to identify factors associated with 
upgrade to cancer upon excision, and, although predic-
tors have been identified, none are yet considered reli-
able enough to justify forgoing treatment for an ADH 
patient. Generally, ADH found in more than two foci 
is a significantly more reliable predictor of DCIS upon 
excision than when found in less than two foci. In one 
study, 39.0 % of cases (16/41) of ADH in more than two 
foci versus 7.3  % with ADH in less than two foci had 
an associated DCIS. In the same study, the lowest risk 
group identified, with no associated DCIS, exhibits one 
or two foci of ADH, micro-calcifications in the lesion, 
and all calcification removed by biopsy (confirmed by 
post-biopsy imaging) [17]. Many clinics have been able to 
identify lower-risk subtypes of ADH that may have a risk 
of associated DCIS of less than 2  %, which is the same 
criterion that indicates a need for imaging follow-up 
for BIRADS-3 lesions [19]. However, the upgrade rates 
remain too high to support only surveillance of these 
atypical lesions, as a breast imaging-reporting and data 
system (BIRADS) score of B3 would indicate [13]. Fur-
ther research aimed at identifying reliable predictors of 
breast cancer risk in ADH patients is needed in order to 
improve the efficiency of therapeutic recommendations, 
as well as to minimize anxiety and procedural risks.
Finally, it is important to mention that though the evi-
dence supports surgical excision of every ADH lesion 
detected by CNB due to its frequent association with 
carcinoma, atypia found on an excision margin is not 
considered a risk factor for cancer recurrence, and as a 
result, in these cases further surgery is not currently rec-
ommended [12].
Biological/molecular findings
Techniques used for classifying ADH and DCIS are not 
always reproducible between centers, and because of this, 
there have been replicated studies aimed at finding stable 
biological and molecular markers for diagnosing ADH 
and DCIS. In two of the studies, done by O’ Connell 
et al. and Arpino et al. respectively, 45 % of ADH patients 
and 77 % of DCIS patients share the loss of heterozygo-
sity (LOH) in chromosome 16p and 17q with ipsilateral 
breast cancer when harvested from the same breast. 
However, the percentage drops to 42 % in ADH and 70 % 
in DCIS when harvested from non-invasive breast. The 
rate of LOH was low at individual loci in ADH, which 
suggests that these individual lesions may be genetically 
heterogeneous. Furthermore, LOH was more common 
in DCIS than in regular hyperplasia, which further indi-
cates that DCIS is a more advanced stage in malignant 
evolution [20]. Because LOH has been identified in ADH, 
DCIS and IDC lesions with similar frequency in a study 
done by Arpino et al., this supports the idea that ADH is 
more of a clonal lesion and belongs in the same spectrum 
as in situ carcinoma [17].
Another study done, by Ma et  al., compared laser-
microdissected samples of ADH, DCIS, and IDC at the 
transcriptome level. This study found that the samples 
from these three stages are very similar in terms of tran-
scriptome level, and that they may derive from the same 
clonal origin, further supporting the claim that ADH is 
a precursor lesion to DCIS. The study also found several 
genetic alterations that occur in the ADH cells that per-
sist through the DCIS and IDC stages; this analysis, how-
ever, did not identify the genetic changes that are distinct 
to each pathological phase of breast cancer, suggesting 
heterogeneity [19].
miRNA as the new biological/molecular marker
Although breast cancer research using genetic markers 
has showed ADH to be a definite genetic precursor to 
DCIS and IDC, it has also proved to be difficult in dis-
tinguishing one pathological phase of breast lesion from 
another. Recent years, there have been many studies that 
have found miRNA expression dysregulation between 
normal, ADH, DCIS and IDC (Tables 1 and 2) [5]. Addi-
tionally, the expression of miRNAs can be measured via 
tissue, plasma, and serum. miRNAs are physiologically 
functional in regulating oncogene or tumor-suppressor 
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Table 1 Serum, Tissue, and Plasma miRNA expression changes in resection samples in breast cancer
Sample type Cancer vs. normal Expression DCIS/ IDC vs. normal Expression References
Serum miR‑451 Down miR‑155 Up [4]
miR‑148a Down [4]
miR‑27a Down [4]
miR‑30b Down [4]
miR‑182 Up [21]
miR‑155 Down miR‑19a Up [22]
miR‑181b Down [22]
miR‑24 Down [22]
miR‑15a Up [23]
miR‑107 Up [23]
miR‑425 Up [23]
miR‑139‑5p Down [23]
miR‑143 Down [23]
miR‑365 Down miR‑181b Up [23]
miR‑155 Up [23]
miR‑1 Up [23]
miR‑133b Up [23]
miR‑92a Up [23]
miR‑18a Up [23]
miR‑145a Down [23]
miR‑29‑b2 up [24]
miR‑155 Up miR‑24 Up [24]
miR‑197 Up [24]
miR‑205 Up
miR‑195 Down [22, 25]
miR‑205 Down [22, 25]
Plasma miR‑148b Up miR‑571 Down [26, 27]
miR‑376c Up
miR‑139‑3p Down
miR‑376c Up miR‑801 Up
miR‑206 Down
miR‑193a‑3p Down
miR‑424 Up
miR‑409‑3p Up miR‑184 Up
miR‑409‑3p Up
miR‑376a Up
miR‑526b Down
miR‑92a Up miR‑519a Down
miR‑148b Up
miR‑190 Up
miR‑127‑3p Up
Serum + tissue miR‑132‑5p Down [28]
miR‑125b‑1‑3p Down
miR‑34c‑5p Down
miR‑382‑3p Down
miR‑485‑5p Down
miR‑323b‑3p Down
miR‑598‑3p Down
miR‑224‑5p Up
miR‑1246 Up
miR‑184 Up
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Table 1 continued
Sample type Cancer vs. normal Expression DCIS/ IDC vs. normal Expression References
Plasma + tissue miR‑16 Up [27]
miR‑27a Up [27]
miR‑150 Up [27]
miR‑191 Up [27]
miR‑200c Up [27]
miR‑210 Up [27]
miR‑451 Up [27]
miR‑145 Down [23, 27]
miR‑21 Up [23, 29]
miR‑145 Down [23]
Tissue miR‑221 Down miR‑10 Down [30]
miR‑29a Up
miR‑21 Up [6, 30]
miR‑99a Down [31]
miR‑151‑3p Up [31]
miR‑145 Down [31]
miR‑210 Up [31]
miR‑10b Down [32]
miR‑125b Down [32]
miR‑132 Down [32]
miR‑155 Up miR‑145 Down [32]
miR‑154‑3p Down [32]
miR‑382‑3p Down [32]
miR‑409‑3p Down [32]
miR‑638 Down [5, 6]
miR‑200a Down [33]
miR‑132 Down [32]
miR‑638 Down [5]
miR‑140 Down [30, 34, 35]
miR‑671‑5p Down [6]
miR‑183 Up [6]
miR‑200b Up [6]
miR‑200c Up [6]
miR‑557 Down [6]
miR‑1207‑5p Down [34]
miR‑874 Down [34]
miR‑30e Up miR‑556‑3p Up [34]
miR‑575 Down [34]
miR‑20a Up [34]
miR‑15a Up [34]
miR‑1202 Down [34]
miR‑141 Up [6, 34]
miR‑19b Up [23]
miR‑1925 Down [23]
miR‑107 Up [23]
miR‑127‑4b Up [23]
miR‑1268 Down [23]
miR‑106b Up [23]
miR‑634 Down [23]
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genes (TSG), and thus, down-regulated or up-regulated 
miRNAs can influence the activity of oncogene or TSG, 
which in turn can affect tumorigenesis [5].
miRNAs are a class of regulatory RNAs that act to 
repress the gene expression at the posttranscriptional level. 
They normally bind to their target mRNAs via base-pairing 
interactions, which results in either degradation of the tar-
get mRNA or inhibition of translation via storage. The miR-
NAs often bind to the mRNAs within the 3′ untranslated 
region (UTR) of the target genes [36]. They are involved 
in various biological processes that are necessary for the 
maintenance of normal physiological state. In relation to 
breast cancer, various miRNAs, such as miRNA-200c, are 
responsible for the regulation of the genetic expression of 
angiogenesis, apoptosis, proliferation, cell-to-cell adhesion, 
etc. [37]. Thus, dysregulation of miRNAs expression can 
lead to dysregulation of cell cycle and growth, which may 
cause uncontrolled tumor growth [26].
Unlike genetic biological markers, miRNAs hold prom-
ise as a future screening marker for breast cancer because 
they can be measured not only from tissue, but also from 
serum or plasma. Three separate studies done by Sochor 
et al., Cuk et al., and Li et al., showed that miR-155, miR-
19a, miR-181b and miR-24, which all act to repress TSG, 
have been up-regulated in DCIS and IDC compared to 
normal and ADH in serum. They also found that miR-
571, miR-206, miR-193a-3p, miR-526b, miR-519a, which 
all act to repress oncogene, have been down-regulated 
in ADH, DCIS and IDC compared to normal in plasma 
(Table  1). Such findings support the idea that the levels 
of miRNA collected in a patient’s serum or plasma are 
not only a possible diagnostic tool for breast cancer, but 
that it can also be a classification tool used to differenti-
ate between ADH, DCIS and IDC if coupled with tissue 
biopsy as a confirmatory test [22–32].
However, the miRNA expression levels measured 
from tissue, serum, and plasma are not necessarily con-
sistent. In a study done by Zhu et al., over 174 miRNAs 
were expressed differently between breast cancer tumors 
and the normal tissue, but only 109 miRNAs differed in 
expression level between serum from patients with breast 
cancer and healthy individuals [28]. Among those miR-
NAS, only ten were common miRNAs (Table  1). Fur-
thermore, the study found that the change in expression 
pattern of miRNA between healthy individuals and indi-
viduals with breast cancer are opposite in serum and tis-
sue samples in 28 miRNAS [28]. Due to inconsistencies in 
expression levels of miRNAs in various sample mediums, 
miRNA biomarkers should be developed tissue-specific.
Conclusions
With the linear model of breast cancer development, it is 
accepted that a breast lesion will develop as follows: ADH 
to DCIS to IDC. With the advent of population screen-
ing with mammography, early diagnosis of breast lesions 
has been possible, however differentiating between the 
benign ADH and precancerous DCIS or IDC remains 
illusive. The presence of ADH is known to be a significant 
factor for the development of breast cancer; however at 
this time, there are currently no clinical, morphological, 
or biological markers that can be used to reliably predict 
whether a premalignant lesion will progress to breast 
cancer. Using miRNA levels found in serum, plasma, 
and tissue as a diagnostic and classification tool seems to 
have a promising future, as there have been hundreds of 
miRNA identified to play a role in breast cancer. We, as 
well as other researchers, have shown there are distinct 
miRNA patterns to distinguish normal breast epithelium 
from cancerous tissue as well as from DCIS/IDC, and 
from ADH. Although the consistency of miRNA expres-
sion changes among serum, plasma, and tissue samples 
still need to be proven, it does not preclude the idea that 
miRNA biomarkers may serve as comparison tool for 
mammography as a new, inexpensive, non-invasive diag-
nostic tool in the future.
Patients diagnosed with a lesion on mammography are 
encouraged to undergo resection, however ADH is not 
malignant and does not need to be removed.
It is of paramount importance to develop a new, inex-
pensive screening tool for breast cancer because it will 
allow wider population, regardless of their socioeco-
nomic status, to receive screening for breast cancer in 
order to detect breast cancer early, and at the same time 
to reduce false alarms. Thus, it will also allow for early 
treatment and a reduction in deaths from breast cancer. 
Therefore there is great value in utilizing miRNA bio-
markers in differentiating ADH from advanced lesions as 
a potential companion tool following mammography and 
Table 2 Tissue miRNA expression changes in  resection 
samples of ADH patients versus normal breast tissue
MiRNA ADH regulation
miR‑1275 Down [34]
miR‑638 Down [34]
miR‑572 Down [34]
miR‑671‑5p Down [34]
miR‑183 Up [6]
miR‑141 Up [6]
miR‑21 Up [6, 34]
miR‑200b Up [6, 34]
miR‑200c Up [6]
miR‑15b Up [23]
miR‑183 Up [23]
miR‑30d Up [23]
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CNB. In the long-term, an understanding of the molecu-
lar mechanisms underlying miRNA biomarkers associ-
ated with breast cancer progression could potentially 
result in the development of novel strategies for disease 
prevention and therapy.
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